Zydus launches oral solution for type 2 diabetes

Published On 2022-07-10 10:15 GMT   |   Update On 2022-07-10 10:15 GMT

Zydus Lifesciences Ltd., a discovery-driven global lifesciences company has launched the molecule Sitagliptin in India under the brand names Sitaglyn and Siglyn to address Type 2 diabetes in India."Sitaglyn and Siglyn will add on to a comprehensive solution for the management of Type 2 diabetes by providing access to quality care to the patients at an affordable cost, approximately 60%...

Login or Register to read the full article

Zydus Lifesciences Ltd., a discovery-driven global lifesciences company has launched the molecule Sitagliptin in India under the brand names Sitaglyn and Siglyn to address Type 2 diabetes in India.

"Sitaglyn and Siglyn will add on to a comprehensive solution for the management of Type 2 diabetes by providing access to quality care to the patients at an affordable cost, approximately 60% lesser than the originator. Sitaglyn and Siglyn offer an oral solution to the patients providing ease of convenience and better compliance," the company stated in its recent release.

For more details, check out the full story on the link below:

Zydus Lifesciences Unveils Anti-Diabetic Drug Molecule Sitagliptin In India


Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News